News summaryViking Therapeutics Investor RelationsNov 15, 2026, 12:00 PM
Viking reports VK2735 Phase 2 VENTURE analysis at ObesityWeek
VKTXpharmaceuticals
At ObesityWeek, held Nov. 14–17, Viking reported that after 13 weeks, 74% of participants receiving weekly subcutaneous VK2735 improved by at least one BMI category, versus 15% on placebo. The company also reported improvements in cardiometabolic markers; up to 14.7% mean weight reduction and 92% of drug-related adverse events mild or moderate were previously reported for VENTURE.